Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/434528
Full metadata record
DC FieldValueLanguage
dc.coverage.spatial
dc.date.accessioned2022-12-30T18:05:44Z-
dc.date.available2022-12-30T18:05:44Z-
dc.identifier.urihttp://hdl.handle.net/10603/434528-
dc.description.abstractEnzalutamide and Dabigatran Etexilate is BCS class II drugs and have low solubility and newlinewhich leading to low bioavailability. In present study, it was successfully formulated hard gelatin capsules of Enzalutamide and Dabigatran Etexilate with conventional process using two solubiliser i.e captex and labrasol in optimized ratio and desired dissolution can achieved. There were increases the dissolution with an increase in the ratio of solubilizer with combinations of Labrasol and captex. Developed compositions had improved dissolution rate which increase the bioavailability. The present invention also provides a solution comprising newlinepolymer and a surfactant comprising a mixture of fatty and sterol in a water miscible solvent, which upon dilution with an aqueous vehicle gives nanodispersion of Enzalutamide. The Present compositions of Dabigatran Etexilate shows higher dissolution rate with 15 minutes as compare to marketed formulations. Stability study indicated there was no such change in the formulation after 6 months. So, it indicates formulation is stable. In vitro dissolution studies revealed a significant improvement in the dissolution behavior of both innovative formulations. Following oral administration in rats, innovative compositions of both drugs provided a marked increase in bioavailability compared with that of the marketed capsules. In addition, in-vitro dissolution efficiency was well correlated to in-vivo pharmacokinetic parameters (Cmax, and AUC). Overall, the present investigation illustrated that both novel formulations providing promising formulation of BCS class II drugs with improved oral absorption and bioavailability.
dc.format.extent
dc.languageEnglish
dc.relation
dc.rightsuniversity
dc.titleNovel Approach for Enhancement of Oral Bioavailability of Bcs Class II Drugs
dc.title.alternative
dc.creator.researcherThakkar, Vishalkumar
dc.subject.keywordcaptex
dc.subject.keywordClinical Pre Clinical and Health
dc.subject.keywordDabigatran
dc.subject.keywordEnzalutamide
dc.subject.keywordLabrasol
dc.subject.keywordPharmacology and Pharmacy
dc.subject.keywordPharmacology and Toxicology
dc.subject.keywordProstate Cancer
dc.description.note
dc.contributor.guidePatel, Dipti H
dc.publisher.placeVadodara
dc.publisher.universityParul University
dc.publisher.institutionPharmaceutical Sciences
dc.date.registered2017
dc.date.completed2022
dc.date.awarded2022
dc.format.dimensions
dc.format.accompanyingmaterialCD
dc.source.universityUniversity
dc.type.degreePh.D.
Appears in Departments:Pharmaceutical Sciences

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File16.39 kBAdobe PDFView/Open
02_prelim pages.pdf1.02 MBAdobe PDFView/Open
03_content.pdf108.14 kBAdobe PDFView/Open
04_abstract.pdf14.79 kBAdobe PDFView/Open
05_chapter 1.pdf806.17 kBAdobe PDFView/Open
06_chapter 2.pdf151.4 kBAdobe PDFView/Open
07_chapter 3.pdf346.59 kBAdobe PDFView/Open
08_chapter 4.pdf2.13 MBAdobe PDFView/Open
09_chapter 5.pdf109.77 kBAdobe PDFView/Open
10_annexure.pdf1.15 MBAdobe PDFView/Open
80_recommendation.pdf126.15 kBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: